AACR IO 2025 (poster): Clinical response to checkpoint inhibitors is associated with distinct gut bacteria that promote anti-tumor immunity through different mechanisms.
https://microbiotica.com/wp-content/uploads/2024/06/Microbiotica_Logo_RGB.svg00immunocityhttps://microbiotica.com/wp-content/uploads/2024/06/Microbiotica_Logo_RGB.svgimmunocity2025-02-26 09:00:442025-03-12 11:33:13AACR IO 2025 (poster): Clinical response to checkpoint inhibitors is associated with distinct gut bacteria that promote anti-tumor immunity through different mechanisms.
